Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01123356 · ClinicalTrials.gov registry record · Phase 2
Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
A Phase 2 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT01123356 is a Phase 2 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 21 participants.
The verdict
NCT01123356, a Phase 2 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this research is to evaluate the safety and effectiveness of the drugs lenalidomide and ofatumumab in the treatment of chronic lymphocytic leukemia (CLL).
Interventions
- DRUG Lenalidomide
- DRUG Ofatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01123356
The ClinicalTrials.gov registry entry for NCT01123356 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.
NCT01123356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01123356 about?
NCT01123356 is a clinical study titled "Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab". The purpose of this research is to evaluate the safety and effectiveness of the drugs lenalidomide and ofatumumab in the treatment of chronic lymphocytic leukemia (CLL).
What is the current status of trial NCT01123356?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2010-05. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01123356?
The interventions under investigation include: Lenalidomide (DRUG), Ofatumumab (DRUG).
Who is sponsoring clinical trial NCT01123356?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.